GoodLife Health vs Hims and Ro: Same Care at a Higher Price?

You have three logins, three bills, and a refill reminder from a company whose clinician you have never spoken to. You pay an insurance premium for a primary care doctor who will not prescribe a GLP-1. You pay a membership app for the prescription. A telehealth clinician you met once signs the renewals. When the scale stopped moving at a higher dose, or the nausea came back, each of the three had a reasonable answer, and none of them had looked at what the other two knew. (The person in this piece is a composite, drawn from situations people describe to us, and not a real patient.)

A fourth option appears at $299 a month, and the suspicion is fair: it could be the same arrangement at a higher price. That suspicion is the search behind GoodLife Health vs Hims and Ro, and it deserves published prices with their dates rather than adjectives. On the drug alone, some of those platforms cost less than we do, and the table below shows it. What the $299 pays for is the step your current arrangements skip, which is finding out why before the dose goes up.

Three prescribers, and nobody holding the whole record

Start with the doctor your premium pays for. The visit was covered, the answer on the GLP-1 was no, and whatever reason came with it, the conversation ended there. Whatever labs that visit produced sit in a portal you rarely open, compared against a population range and filed as normal or not. The relationship you pay for every month has stepped back from the one treatment you are actually on.

Then there is the app. It handles the prescription, the shipping and the reminders, and it is good at those things. Its messages arrive on a schedule: the refill, the check-in form, the email proposing the next dose. The form asks how you feel and what you weigh. It does not ask for blood, and it has never seen the history your doctor holds.

Then there is the signer, a licensed clinician who reviews what the form says and renews the prescription. That is a legitimate service and a narrow one. A signature confirms that a prescription can continue; it does not ask why it stopped working, or why the fatigue arrived with the plateau.

So the facts of your care live in three places that do not talk to each other. When something changes (side effects nobody manages, a stall at a dose that used to work, the news about compounded copies), each of the three can answer the part in front of it, and the part in front of each one is small. Nobody owns the question underneath, which is whether the dose is the problem at all.

You have also been sold to. Each of the three reached you through a promise, and the premium, the app fee and the signer's fee arrive every month whether or not anything improves. A fourth monthly charge should not be accepted on our word. The fair test is the one this piece applies: what each option costs, with the date of the price; how each one is paid; and what each one would do the next time the number on the scale stops moving.

The real difference is how each option gets paid

The clearest way to compare these companies is the one our white paper on how GLP-1 telehealth companies make money sets out. Every one of them is paid in one of three ways: a margin on the medicine, a low membership fee plus billing your insurance, or one flat fee with the medicine sold at the pharmacy's own price. The paper's point is that the way a company gets paid is the pressure its clinicians work under. That does not make anyone good or bad. It decides what the company is rewarded for.

Apply that to the three names in your question.

Hims publishes a bundle. In August 2026 its branded track listed Wegovy including clinical support at $299 a month, oral Wegovy at $249 and Zepbound at $399, and it moved new patients off compounded semaglutide in 2026. Those numbers are real, and our own cost comparison says so plainly. A bundle gives you one figure for the medication and the care together, which is convenient. It also means the price moves with the molecule, so a switch from Wegovy to Zepbound is a step on the bill. Our comparison found no comprehensive quarterly lab panel inside that bundle.

Ro's advertised track, at $149 to $249 a month as of August 2026, is compounded semaglutide: a copy mixed by a pharmacy, not the FDA-reviewed branded product. Branded medication through Ro costs substantially more. The ground under compounded copies has moved. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025, and the last grace periods closed in spring 2025. The agency sets out its position in its statement of concerns about unapproved GLP-1 drugs, and both manufacturers have sued companies selling compounded versions. What remains is a narrow exception for one patient with a documented need the branded product cannot meet. Many people used compounded copies legally during the shortage and did nothing wrong; a business still built on them in 2026 rests on an exception rather than a rule, and the prescribing clinician's license carries the responsibility.

MEDVi does not appear in the comparison chart our Learning Center compiled from public pricing pages, so we quote no figure for it here. Read its pricing page with the three questions above: what the monthly number includes, whether the medication is branded or compounded, and who draws your blood.

Meanwhile the makers now price the drug in public. As published in September 2026, NovoCare lists Wegovy pens at $199 a month for the first two fills, an introductory offer for new patients through December 2026, and $349 a month after that, with the Wegovy pill from $149 a month at lower doses. LillyDirect lists Zepbound vials at $299 to $449 a month depending on dose. Branded medication at a published price is where the field has moved since the shortage ended, and it makes one thing easy to check: whether anything is being added between the maker and you.

Read across the rows and the pattern in your own three arrangements becomes clear. Each prices access to a molecule. None of them is built to read the system around it. Medicine is moving toward testing before treating, with ApoB and fasting insulin read where LDL and glucose alone used to be. Behind a stalled protocol there may be a thyroid that is quietly slowing, a fasting insulin that has been rising for years before glucose showed it, or an ApoB that stays high after the scale improves. Those are blood questions. A check-in form cannot answer them, and a signature does not ask them.

What the $299 does, what year one costs, and what it leaves out

For a reader with three prescribers, the membership is built to replace the app, the signer and the split primary-care relationship with one clinician who stays. GoodLife Health's clinicians are licensed in all fifty states, so the one you see is licensed where you live. Your insurance stays, for the hospital and the catastrophic event; the membership pairs with it and does not replace it. What it replaces is the primary-care relationship, which in your case has been divided three ways.

The order is the difference. Testing comes first: four cardiometabolic lab panels a year, every result in your hands, read with you by the clinician who stays, with asynchronous messaging and video visits between draws. Treatment comes second, and only when a clinician judges it indicated. If a GLP-1 is indicated, it is branded and FDA-approved (Wegovy, Zepbound, Mounjaro or Ozempic), prescribed to the pharmacy you choose at that pharmacy's own price. GoodLife Health sets nothing, sees nothing and takes nothing on the medication. We prescribe no compounded GLP-1, ever, which is what separates this from the compounded track in your question. A clinician may also conclude that a GLP-1 is not what your numbers call for, and that decision is made on your panel rather than on a form.

The money works like this. The membership is $299 a month, month to month, and $598 is charged at sign-up to cover the first two months. If the clinician cannot accept you into care, the $598 is refunded in full; once you are accepted, the first two months are non-refundable. Medication billed by a pharmacy follows that pharmacy's own return and refund policy. The fee is the same whatever medication is indicated and whatever the dose, with no molecule upcharge and no dose upcharge, so nothing in our revenue changes when a dose goes up or a drug is switched. The membership fee is generally eligible for HSA or FSA pre-tax dollars.

Any comparison we publish shows both sides of year one, with the dates of the prices used. Our side is $3,588 for the membership over a year, with medication billed separately by your pharmacy. Our cost comparison, at August 2026 published prices, put the all-in monthly figure at $448 on an oral entry dose to $748 at injectable maintenance. For a bundle, the year-one figure is twelve months of the bundled price at the dose you actually reach; at Hims's August 2026 prices that monthly figure is $249, $299 or $399 depending on the product. For Ro's compounded track it is twelve months at $149 to $249, for a different product class. We give their monthly figures rather than a multiplied total because the dose you reach decides which figure applies, and the same holds for our medication line.

So on branded Wegovy alone, the Hims bundle costs less than we do, and we will not argue otherwise. The case for the membership rests on who answers to your numbers. In the arrangement you have now, the party paid for the prescription is not the party who reads your blood, and the party who reads your blood has stepped away from the prescription. Here one clinician holds both, and the fee stays the same whatever that clinician decides.

What the fee returns is what none of the three produced: the diagnosis a visit never reached, the same markers followed every quarter so a change shows up as a trend, and an end to the eight-minute visit. What it does not do matters as much. It does not promise weight loss, remission or a cure. It does not promise a prescription; your primary care doctor said no, and our clinician may say no too, on your numbers. It does not promise that a plan will cover a medication, which is between you, the plan and the pharmacy. Not everyone is accepted: the path is the eligibility check, the intake, the checkout, then a clinician's review.

Before you add a fourth bill

We do not know whether your plateau has a cause a panel would find, and neither does anyone who has not seen your blood. We do know that the question can be asked this week, whether or not you join.

Ask your primary care office for copies of your most recent labs, and note which markers were drawn and which were not. Ask the app and the signer one question each: who looks at my blood, and when. Write down what you pay each month for the premium, the app and the signer, and multiply each by twelve yourself; that is your current year one, and it belongs beside our $3,588. Then look up the manufacturer's own price for the drug you take, with the date, on NovoCare or LillyDirect, so you can see what a bundle or an app is charging around it.

If the answers come back with labs drawn regularly and a clinician who knows them, you may not need us. If they come back as three shrugs, that is the gap the membership was built for.

Who this is not for

If what you want is branded Wegovy or Zepbound at the lowest possible monthly figure, a published bundle or the manufacturer's direct channel will cost you less, and you should use one. If you want compounded semaglutide at a lower price, we do not prescribe it and will not. If you are shopping for a prescription at $99 online, we are the wrong purchase, and the app you have may already do that well. If you want a membership that guarantees a prescription, a number on the scale, or insurance coverage for a medication, nothing here promises any of those. If you are looking for something to replace your health insurance, this is not that; keep the insurance.

For everyone else, here is the offer in a few sentences. GoodLife Health is $299 a month, month to month, with $598 charged at sign-up for the first two months, refunded in full if the clinician cannot accept you into care and non-refundable once you are accepted. It buys a quarterly cardiometabolic panel, a clinician who stays, and medication, when indicated, prescribed to your pharmacy at that pharmacy's price, with nothing taken on it. It returns the diagnosis your current visits never produced, your markers followed over time, and an end to the eight-minute visit. It is different because it tests first, treats second, and sells neither the drug nor the dose. The time to start is before the next escalation email: you are already paying three parties for care that has never compared notes, and the next dose decision is better made after a panel than before it.

Related Reading

• How GLP-1 Telehealth Companies Make Money: A Plain-Language Whitepaper
• The True Monthly Cost of GLP-1 Telehealth: An Honest Comparison

References

1. NovoCare Pharmacy — Wegovy self-pay pricing (Novo Nordisk). 2026. www.novocare.com/pharmacy/wegovy.html
2. Zepbound Self Pay Journey Program — LillyDirect vial pricing (Eli Lilly). 2026. zepbound.lilly.com/savings
3. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (U.S. Food and Drug Administration). 2025. www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss